Goldman Sachs Moves VRX To Not Rated

Goldman Sachs reports that the Americas Investment Review Committee has determined that the rating and price target for Valeant Pharmaceuticals International, Inc.

should be removed. “Goldman Sachs is acting as a financial advisor in connection with a matter that is fundamental to the reasonable analysis of the rating and price target for this stock,” Goldman Sachs writes. “This ‘Not Rated' status will continue until such time as sufficient information is available, and/or contingencies appear resolved, to allow such analysis. Earnings estimates during this period will be made without regard to the matter.” Valeant Pharmaceuticals International closed Tuesday at $44.39.